TOKYO--(BUSINESS WIRE)--Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc.

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

The Wegovy pill's approval signifies a shift from injectable to oral dosage forms, driven by patient preference for ...

MAPLE GROVE, Minn., Dec. 9, 2025 /PRNewswire/ -- Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis ...

PARAMUS, N.J., July 1, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for cancer and eye diseases, is pleased to share an update ...

Pharmaceutical manufacturing steps are often isolated in space and time. The synthesis, isolation and purification of the drug substance (DS) and the formulation of the drug product (DP) may be ...

FULLERTON, CA, UNITED STATES, July 2, 2025 /EINPresswire.com/ -- Liminatus Pharma today announced that it has entered into a Memorandum of Understanding (MOU) to form ...

POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share ...

Bioprocessing is an umbrella term that describes the research, development, manufacturing, and commercialization of products derived from or used by biological systems. For industrial purposes, ...

POTOMAC, MD / ACCESS Newswire / January 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") is pleased to announce the appointment of Terry McAuliffe, the 72nd Governor of ...

IGC will continue executing on its clinical roadmap, expanding its intellectual-property portfolio, and engaging responsibly with evolving regulatory frameworks governing cannabinoid therapeutics.